# Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

> **NCT01883323** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 12 (actual)

## Conditions studied

- Metastatic, Stage III or Stage IV, Melanoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Tumor-Infiltrating Lymphocytes
- **BIOLOGICAL:** Low-Dose Interleukin

## Key facts

- **NCT ID:** NCT01883323
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883323, "Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01883323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*